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COVID-19 vaccines – less obfuscation, 
more transparency and action
To the Editor: We considered a detailed rebuttal of Schoub’s many 
scientific errors in his response[1] to our editorial.[2] However, it is 
enough to say that the original arguments remain unaddressed  – 
including the scientific, economic and ethical issues (Fig. 1[3] demon­
strates how, as of 4 April, the variant has overwhelmed many African 
countries, despite his assertion to the contrary), and why South Africa 
(SA) is not following World Health Organization advice. This is 
alarming considering his position in leading the Ministerial Advisory 
Committee on Vaccines (MAC­Vac) and his misrepresenting our 
argument as ‘give it a try’.
However, we take specific issue on one point.
Claiming that we are somehow damaging public trust and fuelling 
vaccine hesitancy is a remarkable assertion – given the lack of 
transparency (‘regrettable’, in his words) regarding the government’s 
decision­making, the poor communication, the pharmaceutical deals 
behind closed doors, and the delayed vaccine roll­out, all of which are 
self­evident indictments of government leadership.
Schoub appeals for us to approach him directly rather than 
approaching the ‘media’. The media in this instance refers to the 
SAMJ, SA’s highest­impact medical journal. It is, however, entirely 
appropriate to question government conduct in public when decisions 
reached and implemented have significant implications for the public 
at large. Furthermore, the public is not presented with the rationale 
for decisions of substantial public interest, and the MAC­Vac 
advisories are still not public. On top of multiple public pleas for this, 
by ourselves and others, the Health Justice Initiative has written  to 
him, the head of the main MAC and the Department of Health to 
release the advisories. No response was received from Schoub or the 
main MAC, and the advisories are still not in the public domain.[4]
We acknowledge an error in reference 6, introduced during editing 
by the journal and now corrected, but stand firmly by our statement 
that there is extensive evidence of efficacy against variants, further 
references for which were in the original editorial. An exhaustive and 
updated review on the topic has also recently been produced.[5]
Schoub’s response remains a distraction from a bigger problem. The 
country’s vaccine strategy is being decided without appropriate levels 
of transparency, by individuals with a track record of questionable 
decision­making. All this within the context of a vaccine strategy 
that is woefully behind schedule, even when measured against other 
African countries. By this point SA should have been in the midst of 
a government roll­out at scale instead of still waiting for the first dose 
to be administered.
W D Francois Venter
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Fig. 1. Frequency of B.1.351 in sequences produced since first new variant reported, per country.[3] The overall frequency of the lineage is defined as the number 
of sequences assigned the lineage divided by the total number of sequences from that country in the time since the variant was first sequenced in that country 
(as at 4 April 2021).
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